HGH Fragment 176-191
Also known as: HGH Fragment 176-191, hGH Fragment 176-191, Fragment 176-191, Frag 176-191, HGH Frag
HGH Fragment 176-191 is the C-terminal fragment of human growth hormone studied primarily for its fat-reducing effects without the broader growth-promoting actions of full-length GH. It is a popular research compound for lipolysis.
Last updated
Mechanism of Action
The fragment corresponds to amino acids 176 to 191 of human growth hormone, the region associated with GH's lipolytic activity. In animal models it stimulates lipolysis (fat breakdown) and inhibits lipogenesis, apparently by acting on adipose tissue beta-3 adrenergic signaling and modulating fatty acid metabolism. Because it lacks the residues responsible for GH's effects on growth and insulin resistance, it is reported not to meaningfully raise IGF-1 or blood glucose.
- Half-life
- Short; on the order of 20 to 30 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Stimulates lipolysis and fat breakdown in research models
- Inhibits new fat formation (lipogenesis)
- Does not appreciably raise IGF-1 levels
- Reported minimal effect on blood glucose compared with full GH
- Studied as a targeted fat-loss research agent
- Often combined with GH secretagogues in body-composition research
Potential Side Effects
- Injection-site redness or irritation
- Transient flushing or headache
- Possible fatigue or lethargy
- Limited long-term human safety data
Common Dosing
Research-use only, not medical advice. The research literature commonly references subcutaneous amounts around 250 to 500 mcg per administration, sometimes split before fasted activity, with weight-based scaling in animal studies.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Known hypersensitivity to the peptide
- Pregnancy or breastfeeding
- Active malignancy without oversight
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
Tesamorelin
A stabilized GHRH analog FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Studied for its strong effect on visceral adipose tissue.
MOTS-c
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA region that acts as a regulator of metabolism. It is studied for improving insulin sensitivity, metabolic flexibility, and exercise capacity.
- View
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
2001
- View
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
2000
- View
Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone
1993
- View
Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide
1994